Sort
10,766 grants matching “checkpoint inhibitor”
Targeting the Immunosuppressive Tumor Microenvironment for Colorectal Cancer Treatment
$380,262Qingding Wang · University Of Kentucky · R01 · FY2024 · CA
Mechanism of Mitotic Checkpoint in Mammalian Cells
$380,061Timothy Yen · Research Inst Of Fox Chase Can Ctr · R01 · FY2010 · GM
PS03, a bifunctional RNA therapeutic to induce exhaustion in diabetogenic T cells
$380,000Paolo Serafini · University Of Miami School Of Medicine · R56 · FY2025 · AI
Antitumor-Antibiotics from Marine Microorganisms
$380,000University Of California San Diego · R37 · FY2005 · CA
Quinolinate-induced immune suppression in glioblastoma
$380,000Prakash Chinnaiyan · William Beaumont Hospital Research Inst · R01 · FY2025 · NS
Quinolinate-induced immune suppression in glioblastoma
$380,000Prakash Chinnaiyan · William Beaumont Hospital Research Inst · R01 · FY2023 · NS
Antitumor-Antibiotics from Marine Microorganisms
$380,000University Of California San Diego · R37 · FY2004 · CA
Cancer-targeted local pulmonary immunotherapy with PD-L1 inhibitory peptide secretory genes for the treatment of lung cancer
$380,000Masaaki Tamura · Kansas State University · R15 · FY2017 · CA
New Strategies for Treatment of NRAS Mutant Melanoma after Progression on Immune Checkpoint Inhibitors
$379,970Ann Richmond · Vanderbilt University · R01 · FY2021 · CA
Project 2
$379,776David A Barbie · Dana-Farber Cancer Inst · P50 · FY2023 · CA
Replication Associated Genetic Rearrangements
$379,742Susan Thomas Lovett · Brandeis University · R01 · FY2006 · GM
Delineating how nucleic acid sensing in tumorcells regulate anti-tumor immune responses
$379,690Malay Haldar · University Of Pennsylvania · P01 · FY2025 · CA
Reprogramming the tumormicroenvironment to improve immunotherapy of glioblastoma
$379,634Rakesh K. Jain · Massachusetts General Hospital · R01 · FY2022 · CA
Reprogramming the tumormicroenvironment to improve immunotherapy of glioblastoma
$379,634Rakesh K. Jain · Massachusetts General Hospital · R01 · FY2025 · CA
PPARgamma, Toll-like receptors, and atherosclerosis
$379,598Christopher K Glass · University Of California, San Diego · R01 · FY2007 · HL
DNA damaging therapy and immune response in small cell lung cancer subtypes
$379,504Lauren Averett Byers · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
ST8Sia6 expression on tumors inhibits the immune response
$379,434Virginia Smith Shapiro · Mayo Clinic Rochester · R01 · FY2024 · CA
Delineating how nucleic acid sensing in tumor cells regulate anti-tumor immune responses
$379,354Sunny Shin · University Of Pennsylvania · P01 · FY2023 · CA
Identifying novel therapies targeting Merkel cell carcinoma and tumor microenvironment
$379,343Ling Gao · Southern California Inst For Res/Educ · R01 · FY2023 · CA
DEREGULATION OF CELLULAR IKB KINASES BY HTLV1 TAX
$379,098Vanderbilt University · R01 · FY2002 · CA
Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma
$379,082Ari M. Melnick · Weill Medical Coll Of Cornell Univ · R01 · FY2016 · CA
Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma
$379,082Ari M. Melnick · Weill Medical Coll Of Cornell Univ · R01 · FY2015 · CA
E3 ligase mediated control of Foxp3 expression and immune suppression-mechanisms and potential as immunotherapeutic target
$379,055Drew M. Pardoll · Johns Hopkins University · R01 · FY2022 · AI
A Regulatory Checkpoint in the Pathogenesis of Inflammatory Arthritis
$379,021Christian Stehlik · Northwestern University At Chicago · R01 · FY2017 · AR
Targeting CCR2-expressing myeloid cells to overcome immune checkpoint inhibitor resistance in glioma
$378,934Jeffrey K Harrison · University Of Florida · R01 · FY2021 · NS